101
|
Wang Q, Li G, Liu Z, Tan X, Ding Z, Ma J, Li L, Li D, Han J, Wang B. Naphthalimide Platinum(IV) Compounds as Antitumor Agents with Dual DNA Damage Mechanism to Overcome Cisplatin Resistance. Eur J Inorg Chem 2018. [DOI: 10.1002/ejic.201800799] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Qingpeng Wang
- Institute of Biopharmaceutical Research; Liaocheng University; 252059 Liaocheng P.R. China
| | - Guoshuai Li
- Institute of Biopharmaceutical Research; Liaocheng University; 252059 Liaocheng P.R. China
| | - Zhifang Liu
- Institute of Biopharmaceutical Research; Liaocheng University; 252059 Liaocheng P.R. China
| | - Xiaoxiao Tan
- Institute of Biopharmaceutical Research; Liaocheng University; 252059 Liaocheng P.R. China
| | - Zhuang Ding
- Institute of Biopharmaceutical Research; Liaocheng University; 252059 Liaocheng P.R. China
| | - Jing Ma
- Institute of Chemical Biology; College of Pharmacy; Henan University; 475004 Kaifeng P.R. China
| | - Lanjie Li
- Institute of Biopharmaceutical Research; Liaocheng University; 252059 Liaocheng P.R. China
| | - Dacheng Li
- Institute of Biopharmaceutical Research; Liaocheng University; 252059 Liaocheng P.R. China
| | - Jun Han
- Institute of Biopharmaceutical Research; Liaocheng University; 252059 Liaocheng P.R. China
| | - Bingquan Wang
- Institute of Biopharmaceutical Research; Liaocheng University; 252059 Liaocheng P.R. China
| |
Collapse
|
102
|
Abstract
The success of platinum-based anticancer agents has motivated the exploration of novel metal-based drugs for several decades, whereas problems such as drug-resistance and systemic toxicity hampered their clinical applications and efficacy. Stimuli-responsiveness of some metal complexes offers a good opportunity for designing site-specific prodrugs to maximize the therapeutic efficacy and minimize the side effect of metallodrugs. This review presents a comprehensive and up-to-date overview on the therapeutic stimuli-responsive metallodrugs that have appeared in the past two decades, where stimuli such as redox, pH, enzyme, light, temperature, and so forth were involved. The compounds are classified into three major categories based on the nature of stimuli, that is, endo-stimuli-responsive metallodrugs, exo-stimuli-responsive metallodrugs, and dual-stimuli-responsive metallodrugs. Representative examples of each type are discussed in terms of structure, response mechanism, and potential medical applications. In the end, future opportunities and challenges in this field are tentatively proposed. With diverse metal complexes being introduced, the foci of this review are pointed to platinum and ruthenium complexes.
Collapse
Affiliation(s)
- Xiaohui Wang
- College of Chemistry and Molecular Engineering , Nanjing Tech University , Nanjing 211816 , P. R. China
| | - Xiaoyong Wang
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences , Nanjing University , Nanjing 210023 , P. R. China
| | - Suxing Jin
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences , Nanjing University , Nanjing 210023 , P. R. China
| | - Nafees Muhammad
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry , Sun Yat-Sen University , Guangzhou 510275 , P. R. China
| | - Zijian Guo
- State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering , Nanjing University , Nanjing 210093 , P. R. China
| |
Collapse
|
103
|
Li X, Liu Y, Tian H. Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands. Bioinorg Chem Appl 2018; 2018:8276139. [PMID: 30402082 PMCID: PMC6191961 DOI: 10.1155/2018/8276139] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Revised: 08/19/2018] [Accepted: 09/06/2018] [Indexed: 12/21/2022] Open
Abstract
To overcome the side effects of and resistance to cisplatin, a variety of Pt(IV) prodrugs were designed and synthesized via different modifications including combination with lipid chains to increase hydrophobicity, conjugation with short peptide chains or nanoparticles to improve drug delivery, or addition of bioactive ligands to the axial positions of Pt(IV) complexes to exert dual-function effects. This review summarizes the recent progress in the development of Pt(IV) prodrugs conjugated with bioactive-targeting ligands, including histone deacetylase inhibitors, p53 agonists, alkylating agents, and nonsteroidal anti-inflammatory agents. Although Pt(IV) complexes that conjugated with bioactive ligands show satisfactory anticancer effects, none has been approved for clinical use. Therefore, we hope that this review will contribute to further study and development of Pt(IV) complexes conjugated with bioactive and other ligands.
Collapse
Affiliation(s)
- Xuejiao Li
- Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China
| | - Yahong Liu
- Tianjin Binjiang Pharma, Inc., Tianjin 300192, China
| | - Hongqi Tian
- Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China
| |
Collapse
|
104
|
Ghobadi R, Divsalar A, Harifi-Mood AR, Saboury AA, Eslami-Moghadam M. How a promising anti-cancer derivative of palladium consisting phen-imidazole ligand affects bovine liver catalase functionality. J Photochem Photobiol A Chem 2018. [DOI: 10.1016/j.jphotochem.2018.05.026] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
105
|
Hu J, Chen S, Mao R, Liao C, Yang H, Zhao J. Cytotoxicity, dual-targeting apoptosis induction evaluation of multinuclear cu complexes based on pyrazine-benzimidazole derivative. J Inorg Biochem 2018; 186:246-256. [DOI: 10.1016/j.jinorgbio.2018.06.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2018] [Revised: 06/21/2018] [Accepted: 06/24/2018] [Indexed: 11/16/2022]
|
106
|
Rangone B, Ferrari B, Astesana V, Masiello I, Veneroni P, Zanellato I, Osella D, Bottone MG. A new platinum-based prodrug candidate: Its anticancer effects in B50 neuroblastoma rat cells. Life Sci 2018; 210:166-176. [PMID: 30144454 DOI: 10.1016/j.lfs.2018.08.048] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Revised: 07/27/2018] [Accepted: 08/20/2018] [Indexed: 01/11/2023]
Abstract
AIMS Neuroblastoma is a rare cancer that affects children, mostly under the age of 5. This type of cancer starts in very early forms of immature nerve cells or developing cells found in embryo or fetus. To date cisplatin represents one of the most potent antitumor agent known, however, the onset of systemic side effects and the induction of drug resistance limit its use in the clinic for long-term treatment. In the present study we have analysed the effects of a new compound of platinum(IV) conjugates, named Pt(IV)Ac-POA, which is able to generate a synergistic antineoplastic action when released along with cisplatin upon intracellular Pt(IV) → Pt(II) reduction. MAIN METHODS To assess the growth inhibition of the compounds under investigation, a cell viability test, i.e. the resazurin reduction assay was used on the B50 neuroblastoma rat cells. Further analysis on the cell cycle and metabolic alterations were carried out through flow cytometry. Morphological changes and activation of different cell death pathways after treatment, were observed at transmission electron microscope and by immunocytochemistry at fluorescence microscopy. Protein expression was examined by western blot analysis. KEY FINDINGS This compound bearing bioactive axial ligand, such as the active histone deacetylase inhibitor (HDACi) (2-propynyl)octanoic acid (POA), induced cell death through different pathways at a concentration ten times lower than cisplatin. SIGNIFICANCE The results showed that Pt(IV)Ac-POA could represent a promising improvement of Pt-based chemotherapy against neuroblastoma.
Collapse
Affiliation(s)
- Beatrice Rangone
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale "A. Avogadro", viale Teresa Michel 11, 15121 Alessandria, Italy
| | - Beatrice Ferrari
- Dipartimento di Biologia e Biotecnologie "L. Spallanzani", Università di Pavia, via Ferrata 9, 27100 Pavia, Italy
| | - Valentina Astesana
- Dipartimento di Biologia e Biotecnologie "L. Spallanzani", Università di Pavia, via Ferrata 9, 27100 Pavia, Italy
| | - Irene Masiello
- Dipartimento di Biologia e Biotecnologie "L. Spallanzani", Università di Pavia, via Ferrata 9, 27100 Pavia, Italy
| | - Paola Veneroni
- Dipartimento di Biologia e Biotecnologie "L. Spallanzani", Università di Pavia, via Ferrata 9, 27100 Pavia, Italy
| | - Ilaria Zanellato
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale "A. Avogadro", viale Teresa Michel 11, 15121 Alessandria, Italy
| | - Domenico Osella
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale "A. Avogadro", viale Teresa Michel 11, 15121 Alessandria, Italy
| | - Maria Grazia Bottone
- Dipartimento di Biologia e Biotecnologie "L. Spallanzani", Università di Pavia, via Ferrata 9, 27100 Pavia, Italy.
| |
Collapse
|
107
|
Gabano E, Ravera M, Zanellato I, Tinello S, Gallina A, Rangone B, Gandin V, Marzano C, Bottone MG, Osella D. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate. Dalton Trans 2018; 46:14174-14185. [PMID: 28984330 DOI: 10.1039/c7dt02928d] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The design, synthesis, characterization and biological properties of a Pt(iv) complex containing the very active inhibitor of histone deacetylase (2-propynyl)octanoic acid, POA, as an axial ligand are reported here. The title complex, namely (OC-6-44)-acetatodiamminedichlorido(2-(2-propynyl)octanoato)platinum(iv), 1, containing POA in racemic or in enantiomeric forms, was one/two orders of magnitude more active than cisplatin, depending on the chemo-sensitivity of the cancer cell lines. Moreover, 1 exhibited similar or even better antiproliferative activity than (OC-6-33)-diamminedichloridobis(2-propylpentanoato)platinum(iv), 2, containing two molecules of the well-known histone deacetylase inhibitor 2-propylpentanoic (valproic) acid. The high potency of 1 is likely due to its high cellular accumulation and to the synergism between the DNA-damaging cisplatin and the histone deacetylase inhibitor POA, both released upon the intracellular reduction of 1. Prodrug 1, after oral administration, caused an impressive reduction of the tumor mass (94%) in a model of solid tumor (murine Lewis lung carcinoma), compared to that of the control, whereas (intraperitoneal) cisplatin induced a tumor regression of 75% only. A good accumulation of 1 was observed in the tumor mass. The time course of the body weight attested that cisplatin induced elevated anorexia, whereas treatment with 1 did not induce significant body weight loss throughout the therapeutic experiment.
Collapse
Affiliation(s)
- Elisabetta Gabano
- Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
108
|
Li L, Huang X, Huang R, Gou S, Wang Z, Wang H. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance. Eur J Med Chem 2018; 156:666-679. [PMID: 30031977 DOI: 10.1016/j.ejmech.2018.07.016] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Revised: 07/02/2018] [Accepted: 07/06/2018] [Indexed: 12/16/2022]
Abstract
It is well-known that cisplatin exhibited a broad spectrum of anticancer activities against many solid tumors, but its severe toxicity and drug resistance have largely limited wider clinical applications. Various strategies have been tried to discover new Pt (II) drugs with at least equal activity as well as low toxicity compared to cisplatin, but the inherent problem remains unsolved. Here we report that Pt (IV) complexes comprising a CA-4 analogue, as dual-targeting Pt (IV) prodrug, were synthesized and evaluated for anti-proliferative activity using MTT assay. Among them, complex 19 displayed most potent activity against the tested cancer cell lines, and simultaneously exhibited better cell selectivity between cancer cells and normal cells than that of cisplatin. Mechanism studies revealed that complex 19 effectively induced cell cycle arrest at the G2/M phase and dramatically disrupted the microtubule organization. Moreover, complex 19 significantly induced cell apoptosis and decreased MMP. Importantly, complex 19 significantly inhibited tumor growth in SK-OV-3 xenograft model in vivo without apparent toxicity.
Collapse
Affiliation(s)
- Lingxue Li
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing, 211189, China
| | - Xiaochao Huang
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing, 211189, China
| | - Rizhen Huang
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing, 211189, China
| | - Shaohua Gou
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing, 211189, China.
| | - Zhimei Wang
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing, 211189, China
| | - Hengshan Wang
- State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin, 541004, China.
| |
Collapse
|
109
|
Ma L, Wang N, Ma R, Li C, Xu Z, Tse MK, Zhu G. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV
Anticancer Prodrug. Angew Chem Int Ed Engl 2018. [DOI: 10.1002/ange.201804314] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- Lili Ma
- Department of Chemistry; City University of Hong Kong; 83 Tat Chee Ave. Kowloon Tong Hong Kong SAR P. R. China
- City University of Hong Kong, Shenzhen Research Institute; Shenzhen P. R. China
| | - Na Wang
- Department of Chemistry; City University of Hong Kong; 83 Tat Chee Ave. Kowloon Tong Hong Kong SAR P. R. China
- City University of Hong Kong, Shenzhen Research Institute; Shenzhen P. R. China
| | - Rong Ma
- Department of Chemistry; City University of Hong Kong; 83 Tat Chee Ave. Kowloon Tong Hong Kong SAR P. R. China
| | - Cai Li
- Department of Chemistry; City University of Hong Kong; 83 Tat Chee Ave. Kowloon Tong Hong Kong SAR P. R. China
- City University of Hong Kong, Shenzhen Research Institute; Shenzhen P. R. China
| | - Zoufeng Xu
- Department of Chemistry; City University of Hong Kong; 83 Tat Chee Ave. Kowloon Tong Hong Kong SAR P. R. China
- City University of Hong Kong, Shenzhen Research Institute; Shenzhen P. R. China
| | - Man-Kit Tse
- Department of Chemistry; City University of Hong Kong; 83 Tat Chee Ave. Kowloon Tong Hong Kong SAR P. R. China
| | - Guangyu Zhu
- Department of Chemistry; City University of Hong Kong; 83 Tat Chee Ave. Kowloon Tong Hong Kong SAR P. R. China
- City University of Hong Kong, Shenzhen Research Institute; Shenzhen P. R. China
| |
Collapse
|
110
|
Ma L, Wang N, Ma R, Li C, Xu Z, Tse MK, Zhu G. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt IV Anticancer Prodrug. Angew Chem Int Ed Engl 2018; 57:9098-9102. [PMID: 29806087 DOI: 10.1002/anie.201804314] [Citation(s) in RCA: 53] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Indexed: 02/06/2023]
Abstract
Recently, PtIV prodrugs have attracted much attention as the next generation of platinum-based antineoplastic drug candidates. Here we report the discovery and evaluation of monochalcoplatin, a monocarboxylated PtIV prodrug that is among the most cytotoxic PtIV prodrugs to date. Compared with its dicarboxylated counterpart chalcoplatin, monochalcoplatin accumulates astonishingly effectively and rapidly in cancer cells, which is not ascribed to its lipophilicity. The prodrug is quickly reduced, causes DNA damage, and induces apoptosis, resulting in superior cytotoxicity with IC50 values in the nanomolar range in both cisplatin-sensitive and -resistant cells; these IC50 values are up to 422-fold higher than that of cisplatin. A detailed mechanistic study reveals that monochalcoplatin actively enters cells through a transporter-mediated process. Moreover, monochalcoplatin shows significant antitumor activity in an in vivo colorectal tumor model. Our study implies a practical strategy for the design of more effective PtIV prodrugs to conquer drug resistance by tuning both cellular uptake pathways and activation processes.
Collapse
Affiliation(s)
- Lili Ma
- Department of Chemistry, City University of Hong Kong, 83 Tat Chee Ave., Kowloon Tong, Hong Kong SAR, P. R. China.,City University of Hong Kong, Shenzhen Research Institute, Shenzhen, P. R. China
| | - Na Wang
- Department of Chemistry, City University of Hong Kong, 83 Tat Chee Ave., Kowloon Tong, Hong Kong SAR, P. R. China.,City University of Hong Kong, Shenzhen Research Institute, Shenzhen, P. R. China
| | - Rong Ma
- Department of Chemistry, City University of Hong Kong, 83 Tat Chee Ave., Kowloon Tong, Hong Kong SAR, P. R. China
| | - Cai Li
- Department of Chemistry, City University of Hong Kong, 83 Tat Chee Ave., Kowloon Tong, Hong Kong SAR, P. R. China.,City University of Hong Kong, Shenzhen Research Institute, Shenzhen, P. R. China
| | - Zoufeng Xu
- Department of Chemistry, City University of Hong Kong, 83 Tat Chee Ave., Kowloon Tong, Hong Kong SAR, P. R. China.,City University of Hong Kong, Shenzhen Research Institute, Shenzhen, P. R. China
| | - Man-Kit Tse
- Department of Chemistry, City University of Hong Kong, 83 Tat Chee Ave., Kowloon Tong, Hong Kong SAR, P. R. China
| | - Guangyu Zhu
- Department of Chemistry, City University of Hong Kong, 83 Tat Chee Ave., Kowloon Tong, Hong Kong SAR, P. R. China.,City University of Hong Kong, Shenzhen Research Institute, Shenzhen, P. R. China
| |
Collapse
|
111
|
Biancalana L, Batchelor LK, Funaioli T, Zacchini S, Bortoluzzi M, Pampaloni G, Dyson PJ, Marchetti F. α-Diimines as Versatile, Derivatizable Ligands in Ruthenium(II) p-Cymene Anticancer Complexes. Inorg Chem 2018; 57:6669-6685. [PMID: 29790340 DOI: 10.1021/acs.inorgchem.8b00882] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
α-Diimines are among the most robust and versatile ligands available in synthetic coordination chemistry, possessing finely tunable steric and electronic properties. A series of novel cationic ruthenium(II) p-cymene complexes bearing simple α-diimine ligands, [(η6- p-cymene)RuCl{κ2 N-(HCNR)2}]NO3 (R = Cy, [1]NO3; R = 4-C6H10OH, [2]NO3; R = 4-C6H4OH, [3]NO3), were prepared in near-quantitative yields as their nitrate salts. [2]NO3 displays high water solubility. The potential of the α-diimine ligand in [3]NO3 as a carrier of bioactive molecules was investigated via esterification reactions with the hydroxyl groups. Thus, the double-functionalized derivatives [(η6- p-cymene)RuCl{κ2 N-(HCN(4-C6H4OCO-R))2}]NO3 (R = aspirinate, [5]NO3; valproate, [6]NO3) and also [4]Cl (R = Me) were obtained in good-to-high yields. UV-vis and multinuclear NMR spectroscopy and cyclic voltammetric studies in aqueous solution revealed only minor ruthenium chloride hydrolytic cleavage, biologically accessible reduction potentials, and pH-dependent behavior of [3]NO3. Density functional theory analysis was performed in order to compare the Ru-Cl bond strength in [1]+ with the analogous ethylenediamine complex, showing that the higher stability observed in the former is related to the electron-withdrawing properties of the α-diimine ligand. In vitro cytotoxicity studies were performed against tumorigenic (A2780 and A2780cisR) and nontumorigenic (HEK-293) cell lines, with the complexes bearing simple α-diimine ligands ranging from inactive to IC50 values in the low micromolar range. The complexes functionalized with bioactive components, i.e., [5]NO3 and [6]NO3, exhibited a marked increase in the cytotoxicity with respect to the precursor [3]NO3.
Collapse
Affiliation(s)
- Lorenzo Biancalana
- Dipartimento di Chimica e Chimica Industriale , Università di Pisa , Via G. Moruzzi 13 , I-56124 Pisa , Italy
| | - Lucinda K Batchelor
- Institut des Sciences et Ingénierie Chimiques , Ecole Polytechnique Fédérale de Lausanne , CH-1015 Lausanne , Switzerland
| | - Tiziana Funaioli
- Dipartimento di Chimica e Chimica Industriale , Università di Pisa , Via G. Moruzzi 13 , I-56124 Pisa , Italy
| | - Stefano Zacchini
- Dipartimento di Chimica Industriale "Toso Montanari" , Università di Bologna , Viale Risorgimento 4 , I-40136 Bologna , Italy
| | - Marco Bortoluzzi
- Dipartimento di Scienze Molecolari e Nanosistemi , Università Ca' Foscari Venezia , Via Torino 155 , I-30170 Mestre, Venice , Italy
| | - Guido Pampaloni
- Dipartimento di Chimica e Chimica Industriale , Università di Pisa , Via G. Moruzzi 13 , I-56124 Pisa , Italy
| | - Paul J Dyson
- Institut des Sciences et Ingénierie Chimiques , Ecole Polytechnique Fédérale de Lausanne , CH-1015 Lausanne , Switzerland
| | - Fabio Marchetti
- Dipartimento di Chimica e Chimica Industriale , Università di Pisa , Via G. Moruzzi 13 , I-56124 Pisa , Italy
| |
Collapse
|
112
|
Petruzzella E, Sirota R, Solazzo I, Gandin V, Gibson D. Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance. Chem Sci 2018; 9:4299-4307. [PMID: 29780561 PMCID: PMC5944384 DOI: 10.1039/c8sc00428e] [Citation(s) in RCA: 112] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Accepted: 04/07/2018] [Indexed: 01/11/2023] Open
Abstract
A series of triple action Pt(iv) prodrugs was designed to test the hypothesis that multi-action compounds, where each bioactive moiety intervenes in several cellular processes, might be more effective than a single agent at killing cancer cells. In particular, "triple action" Pt(iv) derivatives of cisplatin, where the axial ligands are inhibitors of cyclooxygenase (COXi), histone deacetylase (HDACi) or pyruvate dehydrogenase kinase (PDKi) were developed. All compounds, ctc-[Pt(NH3)2(COXi)(PDKi)Cl2], ctc-[Pt(NH3)2(COXi)(HDACi)Cl2] and ctc-[Pt(NH3)2(HDACi)(PDKi)Cl2], where COXi = aspirin or ibuprofen, PDKi = dichloroacetate and HDACi = valproate or phenylbutyrate, were significantly more cytotoxic than cisplatin against all cell lines of an in-house panel of human cancer cells. They were particularly effective against thyroid and pancreatic cancer cells in monolayer cytotoxicity tests. Remarkably, in 3D spheroid cancer cell cultures, some triple action compounds showed an antitumor potency up to 50-fold higher than cisplatin against a KRAS mutated pancreatic cancer cell line (PSN-1 cells). Standard biochemical assays classically employed to explore structure activity relationships of platinum drugs, such as cellular uptake and binding to potential biological targets (DNA, HDAC, mitochondria, and COX), do not provide linear correlations with the overall cytotoxicity data. We observed a preferential induction of ROS production and of an anti-mitochondrial effect in cancer cells compared to rapidly dividing non-cancerous cells. Thus, we propose that these new triple action Pt(iv) derivatives of cisplatin are a novel and interesting class of potent and selective cytotoxic agents.
Collapse
Affiliation(s)
- Emanuele Petruzzella
- Institute for Drug Research , School of Pharmacy , The Hebrew University , Jerusalem , 91120 , Israel .
| | - Roman Sirota
- Institute for Drug Research , School of Pharmacy , The Hebrew University , Jerusalem , 91120 , Israel .
| | - Irene Solazzo
- Dipartimento di Scienze del Farmaco , Università di Padova , Via Marzolo 5 , 35131 , Padova , Italy
| | - Valentina Gandin
- Dipartimento di Scienze del Farmaco , Università di Padova , Via Marzolo 5 , 35131 , Padova , Italy
| | - Dan Gibson
- Institute for Drug Research , School of Pharmacy , The Hebrew University , Jerusalem , 91120 , Israel .
| |
Collapse
|
113
|
Antonenko T, Shpakovsky D, Vorobyov M, Gracheva Y, Kharitonashvili E, Dubova L, Shevtsova E, Tafeenko V, Aslanov L, Iksanova A, Shtyrlin Y, Milaeva E. Antioxidative vs
cytotoxic activities of organotin complexes bearing 2,6-di-tert
-butylphenol moieties. Appl Organomet Chem 2018. [DOI: 10.1002/aoc.4381] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- T.A. Antonenko
- Department of Medicinal Chemistry and Fine Organic Synthesis; Lomonosov Moscow State University; Moscow 119991 Russia
| | - D.B. Shpakovsky
- Department of Medicinal Chemistry and Fine Organic Synthesis; Lomonosov Moscow State University; Moscow 119991 Russia
| | - M.A. Vorobyov
- Department of Medicinal Chemistry and Fine Organic Synthesis; Lomonosov Moscow State University; Moscow 119991 Russia
| | - Yu.A. Gracheva
- Department of Medicinal Chemistry and Fine Organic Synthesis; Lomonosov Moscow State University; Moscow 119991 Russia
| | - E.V. Kharitonashvili
- Department of Medicinal Chemistry and Fine Organic Synthesis; Lomonosov Moscow State University; Moscow 119991 Russia
| | - L.G. Dubova
- Institute of Physiologically Active Compounds of Russian Academy of Sciences; Chernogolovka 142432 Russia
| | - E.F. Shevtsova
- Institute of Physiologically Active Compounds of Russian Academy of Sciences; Chernogolovka 142432 Russia
| | - V.A. Tafeenko
- Department of Medicinal Chemistry and Fine Organic Synthesis; Lomonosov Moscow State University; Moscow 119991 Russia
| | - L.A. Aslanov
- Department of Medicinal Chemistry and Fine Organic Synthesis; Lomonosov Moscow State University; Moscow 119991 Russia
| | - A.G. Iksanova
- Kazan (Volga Region) Federal University; Kazan 420008 Russia
| | - Yu.G. Shtyrlin
- Kazan (Volga Region) Federal University; Kazan 420008 Russia
| | - E.R. Milaeva
- Department of Medicinal Chemistry and Fine Organic Synthesis; Lomonosov Moscow State University; Moscow 119991 Russia
- Kazan (Volga Region) Federal University; Kazan 420008 Russia
| |
Collapse
|
114
|
Zhang Z, Zhu Z, Luo C, Zhu C, Zhang C, Guo Z, Wang X. A Potential Bone-Targeting Hypotoxic Platinum(II) Complex with an Unusual Cytostatic Mechanism toward Osteosarcoma Cells. Inorg Chem 2018. [PMID: 29513007 DOI: 10.1021/acs.inorgchem.7b03261] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Osteosarcoma (OS) is the most common primary pediatric bone tumor lethal to children and adolescents. Chemotherapeutic agents such as cisplatin are not effective for OS because of their poor accessibility to this cancer and severe systemic toxicity. In this study, a lipophilic platinum(II) complex bearing a bisphosphonate bone-targeting moiety, cis-[PtL(NH3)2Cl]NO3 {BPP; L = tetraethyl [2-(pyridin-2-yl)ethane-1,1-diyl]bisphosphonate}, was prepared and characterized by NMR, electrospray ionization mass spectrometry, and single-crystal X-ray crystallography. The cytotoxicity of BPP toward OS cell lines U2OS and MG-63 was tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. BPP exhibits moderate inhibition against U2OS cells through a mechanism involving both DNA binding and a mevalonate pathway. The acute toxicity of BPP to mice is 7-fold lower than that of cisplatin. The relative low systemic toxicity may result from the steric hindrance of the ligand, which blocks BPP approaching the bases of DNA. The results suggest that incorporating bisphosphonates into a platinum complex not only enhances its bone-targeting property but also minimizes its reactivity toward DNA and thereby lowers the systematic toxicity of the complex. The diminished cytotoxicity of BPP could be compensated for by increasing the therapeutic dose with marginal harm. This strategy provides a new possibility for overcoming the ineffectiveness and systemic toxicity of platinum drugs in the treatment of OS.
Collapse
Affiliation(s)
- Zhenqin Zhang
- School of Pharmacy , Nanjing Medical University , Nanjing 211166 , People's Republic of China
| | | | | | | | | | | | | |
Collapse
|
115
|
Harper BWJ, Petruzzella E, Sirota R, Faccioli FF, Aldrich-Wright JR, Gandin V, Gibson D. Synthesis, characterization and in vitro and in vivo anticancer activity of Pt(iv) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)]. Dalton Trans 2018; 46:7005-7019. [PMID: 28513693 DOI: 10.1039/c7dt01054k] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
This report describes the synthesis, characterization and biological activity of a series of platinum(iv) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)] (Pt56MeSS) with non-bioactive, lipophilic and bioactive axial ligands. In an attempt to explore the anticancer activity potential of the Pt(iv) derivatives, 2D and 3D cytotoxic screening and a preliminary in vivo study were performed. The average IC50 values of the platinum(iv) derivatives ranged from 1.26 to 5.39 μM, compared with 1.24 μM for Pt56MeSS, suggesting that the axial ligands have a relatively minor effect on the potency of the compounds. Preliminary in vivo studies indicate that the platinum(iv) derivatives of Pt56MeSS are active in vivo and can reduce the tumor to a similar extent to cisplatin.
Collapse
Affiliation(s)
- Benjamin W J Harper
- Institute for Drug Research, School of Pharmacy, The Hebrew University, Jerusalem, 91120, Israel.
| | | | | | | | | | | | | |
Collapse
|
116
|
Štarha P, Trávníček Z, Vančo J, Dvořák Z. Half-Sandwich Ru(II) and Os(II) Bathophenanthroline Complexes Containing a Releasable Dichloroacetato Ligand. Molecules 2018; 23:E420. [PMID: 29443934 PMCID: PMC6017048 DOI: 10.3390/molecules23020420] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Revised: 02/08/2018] [Accepted: 02/12/2018] [Indexed: 12/13/2022] Open
Abstract
We report on the preparation and thorough characterization of cytotoxic half-sandwich complexes [Ru(η⁶-pcym)(bphen)(dca)]PF₆ (Ru-dca) and [Os(η⁶-pcym)(bphen)(dca)]PF₆ (Os-dca) containing dichloroacetate(1-) (dca) as the releasable O-donor ligand bearing its own cytotoxicity; pcym = 1-methyl-4-(propan-2-yl)benzene (p-cymene), bphen = 4,7-diphenyl-1,10-phenanthroline (bathophenanthroline). Complexes Ru-dca and Os-dca hydrolyzed in the water-containing media, which led to the dca ligand release (supported by ¹H NMR and electrospray ionization mass spectra). Mass spectrometry studies revealed that complexes Ru-dca and Os-dca do not interact covalently with the model proteins cytochrome c and lysozyme. Both complexes exhibited slightly higher in vitro cytotoxicity (IC50 = 3.5 μM for Ru-dca, and 2.6 μM for Os-dca) against the A2780 human ovarian carcinoma cells than cisplatin (IC50 = 5.9 μM), while their toxicity on the healthy human hepatocytes was found to be IC50 = 19.1 μM for Ru-dca and IC50 = 19.7 μM for Os-dca. Despite comparable cytotoxicity of complexes Ru-dca and Os-dca, both the complexes modified the cell cycle, mitochondrial membrane potential, and mitochondrial cytochrome c release by a different way, as revealed by flow cytometry experiments. The obtained results point out the different mechanisms of action between the complexes.
Collapse
Affiliation(s)
- Pavel Štarha
- Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, 17. listopadu 12, 771 46 Olomouc, Czech Republic.
| | - Zdeněk Trávníček
- Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, 17. listopadu 12, 771 46 Olomouc, Czech Republic.
| | - Ján Vančo
- Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, 17. listopadu 12, 771 46 Olomouc, Czech Republic.
| | - Zdeněk Dvořák
- Department of Cell Biology and Genetics & Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic.
| |
Collapse
|
117
|
Ma L, Lin X, Li C, Xu Z, Chan CY, Tse MK, Shi P, Zhu G. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug. Inorg Chem 2018; 57:2917-2924. [PMID: 29436828 DOI: 10.1021/acs.inorgchem.8b00053] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Although different types of metal-based anticancer complexes have been synthesized, novel complexes to reduce the serious side effect of cisplatin and conquer cancer metastasis are still highly desired. Here, we report the synthesis, characterization, and biological activity of a novel heterodinuclear Pt(IV)-Ru(II) anticancer prodrug. The Pt(IV)-Ru(II) complex exhibits good stability in both water and PBS solution. Biological evaluation revealed that this bifunctional Pt(IV)-Ru(II) complex utilizes the advantages of two metal centers to have both cytotoxicity and antimetastatic property as designed. Although the complex has comparable cytotoxicities to cisplatin in tested cancer cell lines, this prodrug selectively kills cancer but not normal cells, and the IC50 values of the Pt(IV)-Ru(II) complex are 7-10 times higher than those of cisplatin toward normal cells. The cancer cell selectivity is further demonstrated by a cancer-normal cell coculture system. In addition, the antimetastatic properties of the heterodinuclear complex are assessed by using highly metastatic human breast cancer cells, and the results show that the migration and invasion of cancer cells are effectively restrained after the treatment. Moreover, the Pt(IV)-Ru(II) complex displays lower toxicity than cisplatin in developing zebrafish embryos. We, therefore, report an example of heterodinuclear Pt(IV)-Ru(II) complex not only to defeat both drug resistance and cancer metastasis but also having significantly improved cancer cell selectivity and reduced in vivo toxicity than cisplatin.
Collapse
Affiliation(s)
- Lili Ma
- Department of Chemistry , City University of Hong Kong , 83 Tat Chee Ave , Hong Kong SAR , People's Republic of China.,City University of Hong Kong Shenzhen Research Institute , Shenzhen 518057 , People's Republic of China
| | - Xudong Lin
- Department of Biomedical Engineering , City University of Hong Kong , 83 Tat Chee Ave , Hong Kong SAR , People's Republic of China
| | - Cai Li
- Department of Chemistry , City University of Hong Kong , 83 Tat Chee Ave , Hong Kong SAR , People's Republic of China.,City University of Hong Kong Shenzhen Research Institute , Shenzhen 518057 , People's Republic of China
| | - Zoufeng Xu
- Department of Chemistry , City University of Hong Kong , 83 Tat Chee Ave , Hong Kong SAR , People's Republic of China.,City University of Hong Kong Shenzhen Research Institute , Shenzhen 518057 , People's Republic of China
| | - Chun-Yin Chan
- Department of Chemistry , City University of Hong Kong , 83 Tat Chee Ave , Hong Kong SAR , People's Republic of China
| | - Man-Kit Tse
- Department of Chemistry , City University of Hong Kong , 83 Tat Chee Ave , Hong Kong SAR , People's Republic of China
| | - Peng Shi
- Department of Biomedical Engineering , City University of Hong Kong , 83 Tat Chee Ave , Hong Kong SAR , People's Republic of China
| | - Guangyu Zhu
- Department of Chemistry , City University of Hong Kong , 83 Tat Chee Ave , Hong Kong SAR , People's Republic of China.,City University of Hong Kong Shenzhen Research Institute , Shenzhen 518057 , People's Republic of China
| |
Collapse
|
118
|
Huang X, Hua S, Huang R, Liu Z, Gou S, Wang Z, Liao Z, Wang H. Dual-targeting antitumor hybrids derived from Pt(IV) species and millepachine analogues. Eur J Med Chem 2018; 148:1-25. [PMID: 29448138 DOI: 10.1016/j.ejmech.2018.02.012] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Revised: 02/04/2018] [Accepted: 02/05/2018] [Indexed: 12/21/2022]
Abstract
Many strategies have been developed to circumvent the shortcomings of Pt(II)-based chemotherapy, but the inherent problems still have not been effectively resolved. Here we report a new series of dual-targeting Pt(IV) prodrugs, conjugates of millepachine analogues with the related Pt(IV) complexes derived from cisplatin or oxaliplatin, respectively, which can inhibit tubulin polymerization and induce DNA damage. Among them, compound 19 possessed excellent antitumor activities against the tested human cancer cell lines, and arrested the cell cycle at the G2/M phases and ultimately induced cell apoptosis. Interestingly, its low cytotoxicity toward two human normal cells and sensitivity toward two cisplatin-resistant cells revealed the possibility for cancer therapy. More importantly, 19 displayed excellent antitumor efficacy in the SK-OV-3 xenograft model better than cisplatin and the corresponding millepachine analogue. Our research provided an efficient strategy for multi-targeting antitumor drug development.
Collapse
Affiliation(s)
- Xiaochao Huang
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China
| | - Shixian Hua
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China
| | - Rizhen Huang
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China
| | - Zhikun Liu
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China
| | - Shaohua Gou
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China.
| | - Zhimei Wang
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China
| | - Zhixin Liao
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China
| | - Hengshan Wang
- State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China.
| |
Collapse
|
119
|
Huang X, Huang R, Wang Z, Li L, Gou S, Liao Z, Wang H. Pt(IV) complexes conjugating with chalcone analogue as inhibitors of microtubule polymerization exhibited selective inhibition in human cancer cells. Eur J Med Chem 2018; 146:435-450. [PMID: 29407969 DOI: 10.1016/j.ejmech.2018.01.075] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2017] [Revised: 09/17/2017] [Accepted: 01/23/2018] [Indexed: 12/20/2022]
Abstract
Six novel of Pt(IV) complexes comprising chalcone analogues were synthesized and evaluated for anti-proliferative activity using MTT assay. In vitro evaluation revealed that all Pt(IV) complexes showed better and more potent activity against three human cancer cells including CDDP resistant cells than that of their corresponding mother Pt(II) species. Among them, two representative complexes, 14 and 17, exhibited better cell selectivity between cancer cells and normal cells than CDDP. Molecular docking study indicated that complexes 14 and 17 could bind to the colchicine site of tubulin. Moreover, complexes 14 and 17 also remarkably displayed inhibition of cell migration against HUVEC cells in vitro. Molecular mechanism studies suggested that 14 and 17 induced production of reactive oxygen species (ROS), cell cycle arrest at the G2/M phase, and mitochondria-mediated apoptosis by regulating the expression of Bcl-2 family members.
Collapse
Affiliation(s)
- Xiaochao Huang
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Rizhen Huang
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Zhimei Wang
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Lingxue Li
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Shaohua Gou
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China.
| | - Zhixin Liao
- Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Hengshan Wang
- State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China.
| |
Collapse
|
120
|
Abstract
In this manuscript we focus on Pt(iv) anticancer prodrugs. We explore the main working hypotheses for the design of effective Pt(iv) prodrugs and note the exceptions to the common assumptions that are prevalent in the field. Special attention was devoted to the emerging class of "dual action" Pt(iv) prodrugs, where bioactive ligands are conjugated to the axial positions of platinum in order to obtain orthogonal or complementary effects that will increase the efficacy of killing the cancer cells. We discuss the rationale behind the design of the "dual action" prodrugs and the results of the pharmacological studies obtained. Simultaneous release of two bioactive moieties inside the cancer cells often triggers several processes that together determine the fate of the cell. Pt(iv) complexes provide many opportunities for applying new concepts in targeting, synergistic cell killing and exploiting novel nanodelivery systems.
Collapse
Affiliation(s)
- Dan Gibson
- Institute of Drug Research, School of Pharmacy, The Hebrew University, Jerusalem, Israel.
| |
Collapse
|
121
|
Basu U, Banik B, Wen R, Pathak RK, Dhar S. The Platin-X series: activation, targeting, and delivery. Dalton Trans 2018; 45:12992-3004. [PMID: 27493131 DOI: 10.1039/c6dt01738j] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorganic chemistry. Yet there remains the hunt for the "magic bullet" which can satisfy the requirements of an effective chemotherapeutic drug formulation. Pt(iv) complexes are kinetically more inert than the Pt(ii) congeners and offer the opportunity to append additional functional groups/ligands for prodrug activation, tumor targeting, or drug delivery. The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs. Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery. In this review, we will address the attempts made in our lab to develop Pt(iv) prodrugs that can be activated and delivered using targeted nanotechnology-based delivery platforms.
Collapse
Affiliation(s)
- Uttara Basu
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| | - Bhabatosh Banik
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| | - Ru Wen
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| | - Rakesh K Pathak
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| | - Shanta Dhar
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| |
Collapse
|
122
|
Štarha P, Trávníček Z, Drahoš B, Herchel R, Dvořák Z. Cell-based studies of the first-in-class half-sandwich Ir(III) complex containing histone deacetylase inhibitor 4-phenylbutyrate. Appl Organomet Chem 2018. [DOI: 10.1002/aoc.4246] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Pavel Štarha
- Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials, Faculty of Science; Palacký University in Olomouc; 17. listopadu 12 771 46 Olomouc Czech Republic
| | - Zdeněk Trávníček
- Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials, Faculty of Science; Palacký University in Olomouc; 17. listopadu 12 771 46 Olomouc Czech Republic
| | - Bohuslav Drahoš
- Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials, Faculty of Science; Palacký University in Olomouc; 17. listopadu 12 771 46 Olomouc Czech Republic
| | - Radovan Herchel
- Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials, Faculty of Science; Palacký University in Olomouc; 17. listopadu 12 771 46 Olomouc Czech Republic
| | - Zdeněk Dvořák
- Department of Cell Biology and Genetics & Regional Centre of Advanced Technologies and Materials, Faculty of Science; Palacký University in Olomouc; Šlechtitelů 27 783 71 Olomouc Czech Republic
| |
Collapse
|
123
|
Štarha P, Trávníček Z, Herchel R, Jewula P, Dvořák Z. A potential method to improve the in vitro cytotoxicity of half-sandwich Os(ii) complexes against A2780 cells. Dalton Trans 2018; 47:5714-5724. [DOI: 10.1039/c8dt00193f] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
[Os(η6-pcym)(dpa)(VP)]PF6 (1-VP), containing the histone deacetylase inhibitor valproate, shows ca. 3-fold higher in vitro cytotoxicity against the A2780 human ovarian carcinoma cells than its chlorido analogue [Os(η6-pcym)(dpa)Cl]PF6 (1-Cl).
Collapse
Affiliation(s)
- Pavel Štarha
- Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials
- Faculty of Science
- Palacký University in Olomouc
- 771 46 Olomouc
- Czech Republic
| | - Zdeněk Trávníček
- Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials
- Faculty of Science
- Palacký University in Olomouc
- 771 46 Olomouc
- Czech Republic
| | - Radovan Herchel
- Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials
- Faculty of Science
- Palacký University in Olomouc
- 771 46 Olomouc
- Czech Republic
| | - Pawel Jewula
- Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials
- Faculty of Science
- Palacký University in Olomouc
- 771 46 Olomouc
- Czech Republic
| | - Zdeněk Dvořák
- Department of Cell Biology and Genetics & Regional Centre of Advanced Technologies and Materials
- Faculty of Science
- Palacký University in Olomouc
- 783 71 Olomouc
- Czech Republic
| |
Collapse
|
124
|
Gabano E, Ravera M, Trivero F, Tinello S, Gallina A, Zanellato I, Gariboldi MB, Monti E, Osella D. The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions. Dalton Trans 2018; 47:8268-8282. [DOI: 10.1039/c7dt04614f] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The cisplatin/clofibrato combos are multi-action Pt(iv) complexes active on a panel of human tumor cell lines, also under hypoxic conditions.
Collapse
Affiliation(s)
- Elisabetta Gabano
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - Mauro Ravera
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - Francesca Trivero
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - Stefano Tinello
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - Andrea Gallina
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - Ilaria Zanellato
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - Marzia B. Gariboldi
- Dipartimento di Biotecnologie e Scienze della Vita
- Università dell'Insubria
- 21052 Busto Arsizio
- Italy
| | - Elena Monti
- Dipartimento di Biotecnologie e Scienze della Vita
- Università dell'Insubria
- 21052 Busto Arsizio
- Italy
| | - Domenico Osella
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| |
Collapse
|
125
|
Göschl S, Schreiber-Brynzak E, Pichler V, Cseh K, Heffeter P, Jungwirth U, Jakupec MA, Berger W, Keppler BK. Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models. Metallomics 2017; 9:309-322. [PMID: 28205649 DOI: 10.1039/c6mt00226a] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Using platinum(iv) prodrugs of clinically established platinum(ii) compounds is a strategy to overcome side effects and acquired resistances. We studied four oxaliplatin-derived platinum(iv) complexes with varying axial ligands in various in vitro and in vivo settings. The ability to interfere with DNA (pUC19) in the presence and absence of a reducing agent (ascorbic acid) was investigated in cell-free experiments. Cytotoxicity was compared under normoxic and hypoxic conditions in monolayer cultures and multicellular spheroids of colon carcinoma cell lines. Effects on the cell cycle were investigated by flow cytometry, and the capacity of inducing apoptosis was confirmed by flow cytometry and Western blotting. The anti-cancer activity of one complex was studied in vivo in immunodeficient and immunocompetent mice, and the platinum levels in various organs and the tumor after treatment were quantified. The results demonstrate that modification of the axial ligands can improve the cytotoxic potency. The complexes are able to interfere with plasmid DNA, which is enhanced by co-incubation with a reducing agent, and cause cell cycle perturbations. At higher concentrations, they induce apoptosis, but generate only low levels of reactive oxygen species. Two of the complexes increase the life span of leukemia (L1210) bearing mice, and one showed effects similar to oxaliplatin in a CT26 solid tumor model, despite the low platinum levels in the tumor. As in the case of oxaliplatin, activity in the latter model depends on an intact immune system. These findings show new perspectives for the development of platinum(iv) prodrugs of the anticancer agent oxaliplatin, combining bioreductive properties and immunogenic aspects.
Collapse
Affiliation(s)
- Simone Göschl
- University of Vienna, Institute of Inorganic Chemistry, Waehringer Strasse 42, 1090 Vienna, Austria.
| | | | - Verena Pichler
- University of Vienna, Institute of Inorganic Chemistry, Waehringer Strasse 42, 1090 Vienna, Austria. and University of Vienna, Research Platform "Translational Cancer Therapy Research", Vienna, Austria
| | - Klaudia Cseh
- University of Vienna, Institute of Inorganic Chemistry, Waehringer Strasse 42, 1090 Vienna, Austria.
| | - Petra Heffeter
- University of Vienna, Research Platform "Translational Cancer Therapy Research", Vienna, Austria and Medical University of Vienna, Department of Medicine I, Institute of Cancer Research, Vienna, Austria and Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria
| | - Ute Jungwirth
- Medical University of Vienna, Department of Medicine I, Institute of Cancer Research, Vienna, Austria and The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - Michael A Jakupec
- University of Vienna, Institute of Inorganic Chemistry, Waehringer Strasse 42, 1090 Vienna, Austria. and University of Vienna, Research Platform "Translational Cancer Therapy Research", Vienna, Austria
| | - Walter Berger
- University of Vienna, Research Platform "Translational Cancer Therapy Research", Vienna, Austria and Medical University of Vienna, Department of Medicine I, Institute of Cancer Research, Vienna, Austria and Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria
| | - Bernhard K Keppler
- University of Vienna, Institute of Inorganic Chemistry, Waehringer Strasse 42, 1090 Vienna, Austria. and University of Vienna, Research Platform "Translational Cancer Therapy Research", Vienna, Austria
| |
Collapse
|
126
|
Cheng Q, Shi H, Wang H, Wang J, Liu Y. Asplatin enhances drug efficacy by altering the cellular response. Metallomics 2017; 8:672-8. [PMID: 27125788 DOI: 10.1039/c6mt00066e] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Aspirin, a widely used anti-inflammatory drug, has been shown to be effective for the prevention and remission of cancers (Science, 2012, 337(21) 1471-1473). Asplatin, a Pt(iv) prodrug of cisplatin with the ligation of aspirin (c,c,t-[PtCl2(NH3)2(OH)(aspirin)]), demonstrates significantly higher cytotoxicity than cisplatin towards tumor cells and almost fully overcomes the drug resistance of cisplatin resistant cells. In this work, we have studied the molecular mechanism of asplatin by investigating the cellular response to this compound in order to understand the prominent inhibitory effect on the proliferation of cancer cells. The apoptosis analyses and the related gene expression measurements show that aspirin released from asplatin significantly modulates the cellular response to the platinum agent. Asplatin promotes the apoptosis via the BCL-2 associated mitochondrial pathway. The down-regulation of BCL-2 along with the up-regulation of BAX and BAK enhances the mitochondrial outer membrane permeability, resulting in the cytochrome c release from mitochondria into the cytosol. This event promotes the apoptosis by activation of caspase processing. Consequently, the ligation of aspirin significantly enhances the drug efficacy of the platinum complex in the low micromolar range. The alteration of the cellular response is probably responsible for the circumvention of the cisplatin resistance by asplatin. These results provide an insight into the mechanism of asplatin and provide information for designing new classic platinum drugs.
Collapse
Affiliation(s)
- Qinqin Cheng
- CAS Key Laboratory of Soft Matter Chemistry, CAS High Magnetic Field Laboratory, Department of Chemistry, University of Science and Technology of China, Hefei, Anhui 230026, China.
| | - Hongdong Shi
- CAS Key Laboratory of Soft Matter Chemistry, CAS High Magnetic Field Laboratory, Department of Chemistry, University of Science and Technology of China, Hefei, Anhui 230026, China.
| | - Hongxia Wang
- CAS Key Laboratory of Brain Function and Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
| | - Jun Wang
- CAS Key Laboratory of Brain Function and Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China.
| | - Yangzhong Liu
- CAS Key Laboratory of Soft Matter Chemistry, CAS High Magnetic Field Laboratory, Department of Chemistry, University of Science and Technology of China, Hefei, Anhui 230026, China.
| |
Collapse
|
127
|
Supramolecular cisplatin-vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy. J Control Release 2017; 266:36-46. [DOI: 10.1016/j.jconrel.2017.09.007] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2017] [Revised: 09/04/2017] [Accepted: 09/05/2017] [Indexed: 12/24/2022]
|
128
|
Ye RR, Cao JJ, Tan CP, Ji LN, Mao ZW. Valproic Acid-Functionalized Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents. Chemistry 2017; 23:15166-15176. [DOI: 10.1002/chem.201703157] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2017] [Revised: 08/14/2017] [Indexed: 12/12/2022]
Affiliation(s)
- Rui-Rong Ye
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry; School of Chemistry and Chemical Engineering; Sun Yat-Sen University; Guangzhou 510275 P. R. China
| | - Jian-Jun Cao
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry; School of Chemistry and Chemical Engineering; Sun Yat-Sen University; Guangzhou 510275 P. R. China
| | - Cai-Ping Tan
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry; School of Chemistry and Chemical Engineering; Sun Yat-Sen University; Guangzhou 510275 P. R. China
| | - Liang-Nian Ji
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry; School of Chemistry and Chemical Engineering; Sun Yat-Sen University; Guangzhou 510275 P. R. China
| | - Zong-Wan Mao
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry; School of Chemistry and Chemical Engineering; Sun Yat-Sen University; Guangzhou 510275 P. R. China
| |
Collapse
|
129
|
Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1. Eur J Med Chem 2017; 141:211-220. [PMID: 29031068 DOI: 10.1016/j.ejmech.2017.09.074] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2017] [Revised: 09/17/2017] [Accepted: 09/29/2017] [Indexed: 02/07/2023]
Abstract
Several Pt(IV) prodrugs containing SAA, a histone deacetylases inhibitor, were designed and prepared for multiply targeting genomic DNA, histone deacetylases and PARP-1. The resulting Pt(IV) prodrug had significantly strong antiproliferative activity against the tested cancer cell lines, especially SAA1, derived from the conjugation of cisplatin and SAA, had potent ability to overcome cisplatin resistance. Under the combined action of DNA platination and inhibition of HDACs and PARP-1 activity, the cytotoxic activity of SAA1 was 174-fold higher than cisplatin against cisplatin-resistant SGC7901/CDDP cancer cells. The mechanism of action of SAA1 was preliminarily investigated, in which cellular uptake, cell apoptosis and cell cycle arrest as well as western blot analysis were made by treating SAA1 with SGC7901/CDDP cells. Besides, HDACs inhibition activity and PARP-1 enzyme inhibition of SAA1 were also studied.
Collapse
|
130
|
Raudenska M, Krejcova L, Richtera L, Heger Z, Hrabeta J, Eckschlager T, Stiborova M, Adam V, Kratochvilova M, Masarik M, Gumulec J. VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells. Tumour Biol 2017; 39:1010428317711656. [PMID: 28945187 DOI: 10.1177/1010428317711656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Neuroblastoma represents a malignancy of the sympathetic nervous system characteristic by biological heterogeneity. Thus, chemotherapy exhibits only low effectivity in curing high-risk forms. Previous studies revealed the cytotoxic potential of valproate on neuroblastoma cells. Nevertheless, these studies omitted effects of hypoxia, despite its undeniable tumorigenic role. In this study, we addressed the question whether valproate promotes binding of platinum-based anti-cancer drugs (cisplatin, carboplatin and oxaliplatin) to DNA and role of hypoxia, cellular antioxidant capacity and cisplatin resistance in this process. Following parameters differed significantly when cells were exposed to treatment with platinum-based drugs: elevation of platinum content bound to DNA, elevation of total thiol content, GSH/GSSG ratio, glutathione reductase and peroxidase, superoxide dismutase and elevation of antioxidant capacity. Hypoxia caused a decrease in cytosine/adenine peak, and no changes in platinum-DNA binding properties were observed. After valproate co-treatment, oxidative stress-related parameters and cytosine/adenine peak were only elevated. The amount of platinum bound to DNA was not changed significantly. Valproate is not able to enhance platinum binding to DNA in neuroblastoma cells, neither in case of intrinsic resistance (UKF-NB-4) nor in case of acquired resistance (UKF-NB-4CDDP). Therefore, another mechanism different from increase in platinum binding to DNA should be considered as a synergistic effect of valproate by cisplatin treatment.
Collapse
Affiliation(s)
- Martina Raudenska
- 1 Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.,2 Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic
| | - Ludmila Krejcova
- 2 Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic.,3 Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic
| | - Lukas Richtera
- 2 Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic.,3 Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic
| | - Zbynek Heger
- 2 Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic.,3 Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic
| | - Jan Hrabeta
- 4 Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic
| | - Tomas Eckschlager
- 4 Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic
| | - Marie Stiborova
- 5 Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic
| | - Vojtech Adam
- 2 Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic.,3 Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic
| | - Monika Kratochvilova
- 1 Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.,2 Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic
| | - Michal Masarik
- 1 Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.,2 Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic
| | - Jaromir Gumulec
- 1 Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.,2 Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic
| |
Collapse
|
131
|
Almotairy ARZ, Gandin V, Morrison L, Marzano C, Montagner D, Erxleben A. Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid. J Inorg Biochem 2017; 177:1-7. [PMID: 28918353 DOI: 10.1016/j.jinorgbio.2017.09.009] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Revised: 09/07/2017] [Accepted: 09/08/2017] [Indexed: 11/16/2022]
Abstract
Five new platinum(IV) derivatives of carboplatin each incorporating the histone deacetylase inhibitor 4-phenylbutyrate in axial position were synthesized and characterized by 1H and 195Pt NMR spectroscopy, electrospray ionization mass spectrometry and elemental analysis, namely cis,trans-[Pt(CBDCA)(NH3)2(PBA)(OH)] (1), cis,trans-[Pt(CBDCA)(NH3)2(PBA)2] (2), cis,trans-[Pt(CBDCA)(NH3)2(PBA)(bz)] (3), cis,trans-[Pt(CBDCA)(NH3)2(PBA)(suc)] (4) and cis,trans-[Pt(CBDCA)(NH3)2)(PBA)(ac)] (5) (PBA=4-phenylbutyrate, CBDCA=1,1-cyclobutane dicarboxylate, bz=benzoate, suc=succinate and ac=acetate). The reduction behavior in the presence of ascorbic acid was studied by high performance liquid chromatography. The cytotoxicity against a panel of human tumor cell lines, histone deacetylase (HDAC) inhibitory activity, cellular accumulation and the ability to induce apoptosis were evaluated. The most effective complex, compound 3, was found to be up to ten times more effective than carboplatin and to decrease cellular basal HDAC activity by approximately 18% in A431 human cervical cancer cells.
Collapse
Affiliation(s)
| | - Valentina Gandin
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Liam Morrison
- Earth and Ocean Sciences, School of Natural Sciences and Ryan Institute, National University of Ireland, Galway, Ireland
| | - Cristina Marzano
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | | | - Andrea Erxleben
- School of Chemistry, National University of Ireland, Galway, Ireland.
| |
Collapse
|
132
|
Petruzzella E, Braude JP, Aldrich-Wright JR, Gandin V, Gibson D. A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angew Chem Int Ed Engl 2017; 56:11539-11544. [PMID: 28759160 DOI: 10.1002/anie.201706739] [Citation(s) in RCA: 94] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Indexed: 12/31/2022]
Abstract
We developed a novel PtIV prodrug that simultaneously releases four different bioactive moieties inside the cancer cell. Its cytotoxicity against monolayer cultures (2D) and spheroid (3D) cancer cells is significantly better than cisplatin. It is 200-450-fold more potent than cisplatin against KRAS mutated pancreatic and colon cancers and is 40-fold more selective towards KRAS mutated cells compared to non-cancerous. This is important since RAS proteins play a role in regulating cell differentiation, proliferation, and survival and KRAS is mutated in 90 % of pancreatic adenocarcinomas, 45 % of colorectal cancers, and 35 % of lung adenocarcinomas. The selectivity index, determined by dividing the IC50 value in non-cancerous cells by that of a cancerous cell line, is two-fold better than cisplatin, attesting to preferential cytotoxicity towards neoplastic cells.
Collapse
Affiliation(s)
- Emanuele Petruzzella
- Institute for Drug Research, School of Pharmacy, The Hebrew University, Jerusalem, 91120, Israel
| | - Jeremy Phillip Braude
- Dipartimento di Scienze del Farmaco, Università di Padova, Via Marzolo 5, 35131, Padova, Italy
| | - Janice R Aldrich-Wright
- School of Science and Health, Western Sydney University, Penrith South DC, 1797, NSW, Australia
| | - Valentina Gandin
- Dipartimento di Scienze del Farmaco, Università di Padova, Via Marzolo 5, 35131, Padova, Italy
| | - Dan Gibson
- Institute for Drug Research, School of Pharmacy, The Hebrew University, Jerusalem, 91120, Israel
| |
Collapse
|
133
|
Petruzzella E, Braude JP, Aldrich-Wright JR, Gandin V, Gibson D. A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angew Chem Int Ed Engl 2017. [DOI: 10.1002/ange.201706739] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Emanuele Petruzzella
- Institute for Drug Research; School of Pharmacy; The Hebrew University; Jerusalem 91120 Israel
| | - Jeremy Phillip Braude
- Dipartimento di Scienze del Farmaco; Università di Padova; Via Marzolo 5 35131 Padova Italy
| | | | - Valentina Gandin
- Dipartimento di Scienze del Farmaco; Università di Padova; Via Marzolo 5 35131 Padova Italy
| | - Dan Gibson
- Institute for Drug Research; School of Pharmacy; The Hebrew University; Jerusalem 91120 Israel
| |
Collapse
|
134
|
Zhao J, Xu Z, Lin J, Gou S. Exploring the Hydrolytic Behavior of the Platinum(IV) Complexes with Axial Acetato Ligands. Inorg Chem 2017; 56:9851-9859. [PMID: 28771338 DOI: 10.1021/acs.inorgchem.7b01355] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Platinum(IV) complexes are generally thought to be kinetically inert, and are expected to be stable enough to resist premature aquation before entering the cancer cells. Nevertheless, in this work, complex 2 with axial acetato ligands can hydrolyze relatively quickly under biologically relevant conditions with a half-life of 91.7 min, resulting in the loss of the equatorial chlorido ligand. Further study indicated that the fast hydrolysis of complex 2 may be attributed to the strong σ-donor ability of N-isopropyl-1R,2R-diaminocyclohexane, and an increasing σ-donor ability of the amine group can promote the hydrolysis rate of the corresponding platinum(IV) complex. The experiment results were proven by the corresponding DFT calculation. Our study can help to re-evaluate the aqueous properties of the platinum(IV) complexes with axial acetate, which may be less inert to hydrolysis than expected under biologically relevant conditions.
Collapse
Affiliation(s)
- Jian Zhao
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University , Nanjing 211189, China.,Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University , Nanjing 211189, China
| | - Zichen Xu
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University , Nanjing 211189, China
| | - Jing Lin
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University , Nanjing 211189, China.,Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University , Nanjing 211189, China
| | - Shaohua Gou
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University , Nanjing 211189, China.,Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University , Nanjing 211189, China
| |
Collapse
|
135
|
Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H. Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance. Bioorg Med Chem 2017; 25:4686-4700. [PMID: 28728896 DOI: 10.1016/j.bmc.2017.07.011] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2017] [Revised: 07/04/2017] [Accepted: 07/06/2017] [Indexed: 01/08/2023]
Abstract
Pt(IV) complexes comprising a phenstatin analogue, as dual-targeting Pt(IV) prodrug, were designed and synthesized. They were found not only to carry the DNA binding platinum warhead into the tumor cells, but also to have a small molecular unit to inhibit tubulin polymerization. In vitro evaluation results revealed that Pt(IV) complexes showed better and more potent activity against the test human cancer cells including cisplatin resistant cell lines than their corresponding Pt(II) counterparts. In addition, the Pt(IV) derivative of cisplatin, complex 10, exhibited highly selective inhibition in human cancer cells and displayed no obvious toxicity to two human normal cell lines, respectively. Mechanism study suggested that complex 10 induced cell-cycle arrest at the G2/M phase and caused apoptotic cell death of human lung cancer NCI-H460 cells through the mitochondrial mediated pathway. Moreover, complex 10 effectively inhibited the tumor growth in the NCI-H460 xenograft model.
Collapse
Affiliation(s)
- Xiaochao Huang
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Rizhen Huang
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Shaohua Gou
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China.
| | - Zhimei Wang
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Zhixin Liao
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Hengshan Wang
- State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China.
| |
Collapse
|
136
|
Biancalana L, Batchelor LK, De Palo A, Zacchini S, Pampaloni G, Dyson PJ, Marchetti F. A general strategy to add diversity to ruthenium arene complexes with bioactive organic compounds via a coordinated (4-hydroxyphenyl)diphenylphosphine ligand. Dalton Trans 2017. [PMID: 28627572 DOI: 10.1039/c7dt02062g] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Esterification of (4-hydroxyphenyl)diphenylphosphine, coordinated to the [Ru(η6-p-cymene)Cl2] fragment, allows a series of bioactive carboxylic acids to be introduced directly into the organometallic molecule. Evaluation of the compounds on human ovarian cancer cells reveals synergistic enhancements in their antiproliferative activity relative to their bioactive organic and organometallic precursors.
Collapse
Affiliation(s)
- Lorenzo Biancalana
- Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Via Moruzzi 13, I-56124 Pisa, Italy.
| | - Lucinda K Batchelor
- Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
| | - Alice De Palo
- Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Via Moruzzi 13, I-56124 Pisa, Italy.
| | - Stefano Zacchini
- Dipartimento di Chimica Industriale "Toso Montanari", Università di Bologna, Viale Risorgimento 4, I-40136 Bologna, Italy
| | - Guido Pampaloni
- Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Via Moruzzi 13, I-56124 Pisa, Italy.
| | - Paul J Dyson
- Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
| | - Fabio Marchetti
- Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Via Moruzzi 13, I-56124 Pisa, Italy.
| |
Collapse
|
137
|
Huang X, Huang R, Gou S, Wang Z, Wang H. Anticancer Platinum(IV) Prodrugs Containing Monoaminophosphonate Ester as a Targeting Group Inhibit Matrix Metalloproteinases and Reverse Multidrug Resistance. Bioconjug Chem 2017; 28:1305-1323. [PMID: 28276682 DOI: 10.1021/acs.bioconjchem.7b00117] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A novel class of platinum(IV) complexes comprising a monoaminophosphonate ester moiety, which can not only act as a bone-targeting group but also inhibit matrix metalloproteinases (MMPs), were designed and synthesized. Biological assay of these compounds showed that they had potent antitumor activities against the tested cancer cell lines compared with cisplatin and oxaliplatin and indicated low cytotoxicity to human normal liver cells. Particularly, the platinum(IV) complexes were very sensitive to cisplatin resistant cancer cell lines. The corresponding structure-activity relationships were studied and discussed. Related mechanism study revealed that the typical complex 11 caused cell cycle arrest at S phase and induced apoptosis in Bel-7404 cells via a mitochondrial-dependent apoptosis pathway. Moreover, complex 11 had potent ability to inhibit the tumor growth in the NCI-H460 xenograft model comparable to cisplatin.
Collapse
Affiliation(s)
| | | | | | | | - Hengshan Wang
- State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University , Guilin 541004, China
| |
Collapse
|
138
|
Qin X, Xu G, Chen F, Fang L, Gou S. Novel platinum(IV) complexes conjugated with a wogonin derivative as multi-targeted anticancer agents. Bioorg Med Chem 2017; 25:2507-2517. [PMID: 28314511 DOI: 10.1016/j.bmc.2017.03.007] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2017] [Accepted: 03/05/2017] [Indexed: 12/01/2022]
Abstract
Platinum-based complexes like cisplatin and oxaliplatin are well known the mainstay of chemotherapy regimens on clinic. Wogonin, a natural product that possesses wide biological activities, is now in phase I clinical test as an anticancer agent in China. Herein reported are a series of novel Pt(IV) complexes that conjugated a wogonin derivative (compound 3) to the axial position via a linker group. After being tethered to the platinum(IV) complexes, the wogonin derivative provided multiple anticancer effects, especially in compound 10, a fusion containing wogonin and cisplatin units. Compound 10 not only inherited the genotoxicity from cisplatin, but also obtained the COX inhibitory property from the wogonin derivative. Further mechanistic investigation revealed that compound 10 caused the accumulation of ROS, decreased the mitochondrial membrane potential (ΔΨm) and then activated the p53 pathway. Overall, the research demonstrates that the "integrative" prodrug can be an effective strategy to promote the anticancer potency of Pt-based drugs for cancer treatment.
Collapse
Affiliation(s)
- Xiaodong Qin
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China
| | - Gang Xu
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Feihong Chen
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Lei Fang
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China.
| | - Shaohua Gou
- Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China.
| |
Collapse
|
139
|
Kenny RG, Chuah SW, Crawford A, Marmion CJ. Platinum(IV) Prodrugs - A Step Closer to Ehrlich's Vision? Eur J Inorg Chem 2017. [DOI: 10.1002/ejic.201601278] [Citation(s) in RCA: 105] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Reece G. Kenny
- Department of Pharmaceutical & Medicinal Chemistry; Royal College of Surgeons in Ireland; 123 St. Stephen's Green 2 Dublin Ireland
| | - Su Wen Chuah
- Department of Pharmaceutical & Medicinal Chemistry; Royal College of Surgeons in Ireland; 123 St. Stephen's Green 2 Dublin Ireland
| | - Alanna Crawford
- Department of Pharmaceutical & Medicinal Chemistry; Royal College of Surgeons in Ireland; 123 St. Stephen's Green 2 Dublin Ireland
| | - Celine J. Marmion
- Department of Pharmaceutical & Medicinal Chemistry; Royal College of Surgeons in Ireland; 123 St. Stephen's Green 2 Dublin Ireland
| |
Collapse
|
140
|
Gu Z, Li Y, Ma S, Li S, Zhou G, Ding S, Zhang J, Wang S, Zhou C. Synthesis, cytotoxic evaluation and DNA binding study of 9-fluoro-6H-indolo[2,3-b]quinoxaline derivatives. RSC Adv 2017. [DOI: 10.1039/c7ra08138c] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
New quaternary ammonium salts of 9-fluoro-6H-indolo[2,3-b] derivatives were synthesized. These compounds possessed enhanced DNA binding ability and improved antitumor activity.
Collapse
Affiliation(s)
- Zhenyu Gu
- Key Laboratory of Chemical Biology of Hebei Province
- Key Laboratory of Medicinal Chemistry and Molecular Diagnosis
- Ministry of Education
- College of Chemistry & Environmental Science
- Hebei University
| | - Yanci Li
- Key Laboratory of Chemical Biology of Hebei Province
- Key Laboratory of Medicinal Chemistry and Molecular Diagnosis
- Ministry of Education
- College of Chemistry & Environmental Science
- Hebei University
| | - Songliang Ma
- Key Laboratory of Chemical Biology of Hebei Province
- Key Laboratory of Medicinal Chemistry and Molecular Diagnosis
- Ministry of Education
- College of Chemistry & Environmental Science
- Hebei University
| | - Shenghui Li
- Key Laboratory of Chemical Biology of Hebei Province
- Key Laboratory of Medicinal Chemistry and Molecular Diagnosis
- Ministry of Education
- College of Chemistry & Environmental Science
- Hebei University
| | - Guoqiang Zhou
- Key Laboratory of Chemical Biology of Hebei Province
- Key Laboratory of Medicinal Chemistry and Molecular Diagnosis
- Ministry of Education
- College of Chemistry & Environmental Science
- Hebei University
| | - Shan Ding
- Key Laboratory of Chemical Biology of Hebei Province
- Key Laboratory of Medicinal Chemistry and Molecular Diagnosis
- Ministry of Education
- College of Chemistry & Environmental Science
- Hebei University
| | - Jinchao Zhang
- Key Laboratory of Chemical Biology of Hebei Province
- Key Laboratory of Medicinal Chemistry and Molecular Diagnosis
- Ministry of Education
- College of Chemistry & Environmental Science
- Hebei University
| | - Shuxiang Wang
- Key Laboratory of Chemical Biology of Hebei Province
- Key Laboratory of Medicinal Chemistry and Molecular Diagnosis
- Ministry of Education
- College of Chemistry & Environmental Science
- Hebei University
| | - Chuanqi Zhou
- Key Laboratory of Chemical Biology of Hebei Province
- Key Laboratory of Medicinal Chemistry and Molecular Diagnosis
- Ministry of Education
- College of Chemistry & Environmental Science
- Hebei University
| |
Collapse
|
141
|
Ravera M, Gabano E, Zanellato I, Gallina A, Perin E, Arrais A, Cantamessa S, Osella D. Cisplatin and valproate released from the bifunctional [Pt(IV)Cl2(NH3)2(valproato)2] antitumor prodrug or from liposome formulations: who does what? Dalton Trans 2017; 46:1559-1566. [DOI: 10.1039/c6dt03749f] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Comparison between the antiproliferative properties of a Pt(iv)-valproato complex and its metabolites indicates that the former is more active because it is unremoved from cells.
Collapse
Affiliation(s)
- M. Ravera
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - E. Gabano
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - I. Zanellato
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - A. Gallina
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - E. Perin
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - A. Arrais
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - S. Cantamessa
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| | - D. Osella
- Dipartimento di Scienze e Innovazione Tecnologica
- Università del Piemonte Orientale
- 15121 Alessandria
- Italy
| |
Collapse
|
142
|
Half-Sandwich Ru(II) Halogenido, Valproato and 4-Phenylbutyrato Complexes Containing 2,2'-Dipyridylamine: Synthesis, Characterization, Solution Chemistry and In Vitro Cytotoxicity. Molecules 2016; 21:molecules21121725. [PMID: 27983703 PMCID: PMC6274116 DOI: 10.3390/molecules21121725] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Revised: 12/12/2016] [Accepted: 12/13/2016] [Indexed: 12/15/2022] Open
Abstract
Halogenido and carboxylato Ru(II) half-sandwich complexes of the general composition [Ru(η6-p-cym)(dpa)X]PF6 (1–5) were prepared and thoroughly characterized with various techniques (e.g., mass spectrometry, NMR spectroscopy and X-ray analysis); dpa = 2,2′-dipyridylamine; p-cym = p-cymene; X = Cl− (for 1), Br− (for 2), I− (for 3), valproate(1−) (for 4) or 4-phenylbutyrate(1−) (for 5). A single-crystal X-ray analysis showed a pseudo-octahedral piano-stool geometry of [Ru(η6-p-cym)(dpa)I]PF6 (3), with a η6-coordinated p-cymene, bidentate N-donor dpa ligand and iodido ligand coordinated to the Ru(II) atom. The results of the 1H-NMR solution behaviour studies proved that the complexes 1–5 hydrolyse were in the mixture of solvents used (10% MeOD-d4/90% D2O). Complexes 1–5 were in vitro inactive against the A2780 human ovarian carcinoma cell line, up to the highest tested concentration (IC50 > 100 μM).
Collapse
|
143
|
Wang Z, Xu Z, Zhu G. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance. Angew Chem Int Ed Engl 2016; 55:15564-15568. [PMID: 27736029 DOI: 10.1002/anie.201608936] [Citation(s) in RCA: 93] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Indexed: 11/11/2022]
Abstract
DNA damage response plays a key role not only in maintaining genome integrity but also in mediating the antitumor efficacy of DNA-damaging antineoplastic drugs. Herein, we report the rational design and evaluation of a PtIV anticancer prodrug inhibiting nucleotide excision repair (NER), one of the most pivotal processes after the formation of cisplatin-induced DNA damage that deactivates the drug and leads to drug resistance in the clinic. This dual-action prodrug enters cells efficiently and causes DNA damage while simultaneously inhibiting NER to promote apoptotic response. The prodrug is strongly active against the proliferation of cisplatin-resistant human cancer cells with an up to 88-fold increase in growth inhibition compared with cisplatin, and the prodrug is much more active than a mixture of cisplatin and an NER inhibitor. Our study highlights the importance of targeting downstream pathways after the formation of Pt-induced DNA damage as a novel strategy to conquer cisplatin resistance.
Collapse
Affiliation(s)
- Zhigang Wang
- Department of Biology and Chemistry, City University of Hong Kong, 83 Tat Chee Ave, Kowloon Tong, Hong Kong SAR, P.R. China.,City University of Hong Kong, Shenzhen Research Institute, Shenzhen, P.R. China
| | - Zoufeng Xu
- Department of Biology and Chemistry, City University of Hong Kong, 83 Tat Chee Ave, Kowloon Tong, Hong Kong SAR, P.R. China.,City University of Hong Kong, Shenzhen Research Institute, Shenzhen, P.R. China
| | - Guangyu Zhu
- Department of Biology and Chemistry, City University of Hong Kong, 83 Tat Chee Ave, Kowloon Tong, Hong Kong SAR, P.R. China.,City University of Hong Kong, Shenzhen Research Institute, Shenzhen, P.R. China
| |
Collapse
|
144
|
Wang Z, Xu Z, Zhu G. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance. Angew Chem Int Ed Engl 2016. [DOI: 10.1002/ange.201608936] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- Zhigang Wang
- Department of Biology and Chemistry; City University of Hong Kong; 83 Tat Chee Ave Kowloon Tong Hong Kong SAR P.R. China
- City University of Hong Kong, Shenzhen Research Institute; Shenzhen P.R. China
| | - Zoufeng Xu
- Department of Biology and Chemistry; City University of Hong Kong; 83 Tat Chee Ave Kowloon Tong Hong Kong SAR P.R. China
- City University of Hong Kong, Shenzhen Research Institute; Shenzhen P.R. China
| | - Guangyu Zhu
- Department of Biology and Chemistry; City University of Hong Kong; 83 Tat Chee Ave Kowloon Tong Hong Kong SAR P.R. China
- City University of Hong Kong, Shenzhen Research Institute; Shenzhen P.R. China
| |
Collapse
|
145
|
Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H. Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action. Bioconjug Chem 2016; 27:2132-48. [PMID: 27494235 DOI: 10.1021/acs.bioconjchem.6b00353] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Three new Pt(IV) complexes comprising a combretastatin A-4 analogue were designed and synthesized. The resulting antitumor Pt(IV) complexes could significantly improve the antiproliferative activity and overcome the drug resistance of cisplatin in vitro. Interestingly, these novel compounds not only can carry the DNA binding Pt(II) warhead into the cancer cells but also have a small molecule fragment that can inhibit tubulin polymerization. Among them, complex 13, which was attached to an inhibitor of tubulin at one axial position of Pt(IV) octahedral coordination sphere, could effectively enter cancer cells, arrest the cell cycle in HepG-2 cancer cells at G2/M phases, and induce activation of caspases triggering apoptotic signaling via the mitochondrial-dependent apoptosis pathways. Moreover, complex 13 has the ability to effectively inhibit the tumor growth in the HepG-2 xenograft model without causing significant loss of animal body weight in comparison with cisplatin.
Collapse
Affiliation(s)
| | | | | | | | | | - Hengshan Wang
- State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University , Guilin 541004, China
| |
Collapse
|
146
|
Tolan D, Gandin V, Morrison L, El-Nahas A, Marzano C, Montagner D, Erxleben A. Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position. Sci Rep 2016; 6:29367. [PMID: 27404565 PMCID: PMC4941645 DOI: 10.1038/srep29367] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2016] [Accepted: 06/07/2016] [Indexed: 12/18/2022] Open
Abstract
The use of Pt(IV) complexes as pro-drugs that are activated by intracellular reduction is a widely investigated approach to overcome the limitations of Pt(II) anticancer agents. A series of ten mono- and bis-carboxylated Pt(IV) complexes with axial indole-3-acetic acid (IAA) and indole-3-propionic acid (IPA) ligands were synthesized and characterized by elemental analysis, ESI-MS, FT-IR, (1)H and (195)Pt NMR spectroscopy. Cellular uptake, DNA platination and cytotoxicity against a panel of human tumor cell lines were evaluated. All the complexes are able to overcome cisplatin-resistance and the most potent complex, cis,cis,trans-[Pt(NH3)2Cl2(IPA)(OH)] was on average three times more active than cisplatin. Mechanistic studies revealed that the trend in cytotoxicity of the Pt(IV) complexes is primarily consistent with their ability to accumulate into cancer cells and to increase intracellular basal reactive oxygen species levels, which in turn results in the loss of mitochondrial membrane potential and apoptosis induction. The role of the indole acid ligand as a redox modulator is discussed.
Collapse
Affiliation(s)
- Dina Tolan
- School of Chemistry, National University of Ireland, Galway, Ireland.,Department of Chemistry, Faculty of Science, El-Menoufia University, Shebin El-Kom, Egypt
| | - Valentina Gandin
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Italy
| | - Liam Morrison
- Earth and Ocean Sciences, School of Natural Sciences and Ryan Institute, National University of Ireland, Galway, Ireland
| | - Ahmed El-Nahas
- Department of Chemistry, Faculty of Science, El-Menoufia University, Shebin El-Kom, Egypt
| | - Cristina Marzano
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Italy
| | - Diego Montagner
- School of Chemistry, National University of Ireland, Galway, Ireland.,Department of Chemistry, National University of Ireland, Maynooth, Ireland
| | - Andrea Erxleben
- School of Chemistry, National University of Ireland, Galway, Ireland
| |
Collapse
|